ST6GAL1 and colonic neoplasm: In colon cancer cells, silencing of ST6GAL1 increased the anti-cancer effect of the EGFR inhibitor gefitinib, whereas ST6GAL1 overexpression decreased the cytotoxic effect of gefitinib [108].